Abstract
The toxicity to cells and animals of type 1 and toxic and non-toxic type 2 Ribosome-Inactivating Proteins (RIP) is discussed in correlation with their catalytic activity, resulting in ribosome inactivation and apoptosis. The symptoms and histopathological lesions induced by RIP to animals and humans is also reviewed.
Keywords: cytotoxicity, toxicity to animals, toxicity to humans, type 1 ribosome-inactivating proteins, toxic type 2 ribosome-inactivating proteins, non-toxic type 2 ribosome-inactivating proteins
Mini-Reviews in Medicinal Chemistry
Title: Cytotoxicity and Toxicity to Animals and Humans of Ribosome-Inactivating Proteins
Volume: 4 Issue: 5
Author(s): Maria Giulia Battelli
Affiliation:
Keywords: cytotoxicity, toxicity to animals, toxicity to humans, type 1 ribosome-inactivating proteins, toxic type 2 ribosome-inactivating proteins, non-toxic type 2 ribosome-inactivating proteins
Abstract: The toxicity to cells and animals of type 1 and toxic and non-toxic type 2 Ribosome-Inactivating Proteins (RIP) is discussed in correlation with their catalytic activity, resulting in ribosome inactivation and apoptosis. The symptoms and histopathological lesions induced by RIP to animals and humans is also reviewed.
Export Options
About this article
Cite this article as:
Battelli Giulia Maria, Cytotoxicity and Toxicity to Animals and Humans of Ribosome-Inactivating Proteins, Mini-Reviews in Medicinal Chemistry 2004; 4 (5) . https://dx.doi.org/10.2174/1389557043403819
DOI https://dx.doi.org/10.2174/1389557043403819 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology Recent Advances in Developing Ophthalmic Formulations: A Patent Review
Recent Patents on Drug Delivery & Formulation Hypersensitivity Reactions to Ophthalmic Products
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part I Nitric Oxide Synthesis and Action
Vascular Disease Prevention (Discontinued) Theory and Application of Microdialysis in Pharmacokinetic Studies
Current Drug Metabolism Effects of Oral L-Citrulline Supplementation on Lipoprotein Oxidation and Endothelial Dysfunction in Humans with Vasospastic Angina
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Fluoroquinolones: Blessings Or Curses
Current Drug Targets Human Microdialysis
Current Pharmaceutical Biotechnology Abnormal Insulin Signaling: Early Detection of Silent Coronary Artery Disease-Erectile Dysfunction?
Current Pharmaceutical Design The Effect of Serotonin 5-HT2 Receptor Inhibitor on Vasomotor Responses
Vascular Disease Prevention (Discontinued) Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets The Role of Omega-3 Polyunsaturated Fatty Acids Supplementation in Childhood: A Review
Recent Patents on Cardiovascular Drug Discovery Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan
Current Drug Safety Design, Synthesis and Biological Screening of Some Pyridinylpyrazole and Pyridinylisoxazole Derivatives as Potential Anti-inflammatory, Analgesic, Antipyretic and Antimicrobial Agents
Medicinal Chemistry Tomographic Imaging Methods and Gated Technique in Nuclear Cardiology: A Review on Current Status and Future Developments
Recent Patents on Medical Imaging Therapeutic Effects and Mechanisms of Action of Cyclosporine A Ophthalmic Solution in the Treatment of Vernal Keratoconjunctivitis
Current Pharmaceutical Analysis Potassium Channels and Uterine Vascular Adaptation to Pregnancy and Chronic Hypoxia
Current Vascular Pharmacology Pharmacological Management of No Reflow During Percutaneous Coronary Intervention
Current Vascular Pharmacology Regulation of Blood Flow by Prostaglandins
Current Vascular Pharmacology Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued)